Hannah Valantine, Director at BridgeBio Pharma, Inc. (BBIO), sold 2,915 shares at $30.00 ($87K) on 2023-11-15, disclosed to the SEC on 2023-11-17.
Scheduled sale ($87k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CDNA | SELL | 2026-06-16 | $280K | — | Filing → |
| BBIO | SELL | 2026-03-12 | $624K | — | Filing → |
| BBIO | SELL | 2026-03-03 | $1.7M | — | Filing → |